Investor Relations

OPKO Granted Patent from US Patent & Trademark Office for RAYALDEE more »

OPKO's Long-Acting Clotting Factor VIIa-CTP Receives Positive Opinion For Three Orphan Drug Designations in Europe more »

OPKO Granted Patent from European Patent Office for Lagova™ more »

Strong Data from Lagova™ Phase II Clinical Study Presented during Webcast more »

Investor Relations

We are committed to serving the best interests of our shareholders. You will find key shareholder information and financial reports available to help put OPKO Health, Inc.'s financial performance into perspective.

  • Events

Jun 24, 2014 - 8:30 AM
Lagova Phase 2 Data Conference Call
Webcast Listen to webcast
PDF View Presentation
Jun 3, 2014 - 2:30 PM ET
Jefferies 2014 Global Healthcare Conference
Webcast Listen to webcast
PDF View Presentation

  • Stock Information


Ticker OPK Exchange NYSE
Last Price 9.00 Change 0.13 down
Open 9.08 Previous Close 9.13
Day High 9.22 Day Low 8.98
52-Week High 12.95 52-Week Low 7.32
Quotes delayed at least 20 minutes. Information provided by eSignal.